

## Fibrinogen Binding Inhibitor Peptide

Cat. No.:	HY-P1507
CAS No.:	89105-94-2
Molecular Formula:	C <sub>50</sub> H <sub>80</sub> N <sub>18</sub> O <sub>16</sub>
Molecular Weight:	1189.28
Sequence:	His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val
Sequence Shortening:	HHLGGAKQAGDV
Target:	Others
Pathway:	Others
Storage:	Sealed storage, away from moisture
	Powder    -80°C    2 years
	-20°C    1 year

### HHLGGAKQAGDV

\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### SOLVENT & SOLUBILITY

In Vitro	H <sub>2</sub> O : 100 mg/mL (84.08 mM; Need ultrasonic)				
	DMSO : 100 mg/mL (84.08 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration	Mass 1 mg	5 mg	10 mg
		1 mM	0.8408 mL	4.2042 mL	8.4084 mL
		5 mM	0.1682 mL	0.8408 mL	1.6817 mL
10 mM		0.0841 mL	0.4204 mL	0.8408 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (2.10 mM); Suspended solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.10 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (2.10 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

Description	Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.
-------------	--

## In Vitro

Glycoprotein (GP) IIb/IIIa, which exists on the membrane of platelets, changes its form from inactive to active when platelets adhere to collagen exposed on sites of vascular injury. In the circulation, platelet aggregation is mediated by fibrinogen by bridging adjacent platelets through GPIIb/IIIa in an activation-dependent manner. A dodecapeptide HHLGGAKQAGDV (H12), corresponding to the fibrinogen  $\gamma$ -chain carboxy-terminal sequence ( $\gamma$ 400-411), is a specific binding site of the ligand for activated GPIIb/IIIa[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Okamura Y, et al. Release abilities of adenosine diphosphate from phospholipid vesicles with different membraneproperties and their hemostatic effects as a platelet substitute. J Control Release. 2010 Dec 20;148(3):373-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA